Literature DB >> 2317262

Bromocriptine produces decreases in cocaine self-administration in the rat.

C B Hubner1, G F Koob.   

Abstract

The effect of bromocriptine pretreatment was investigated in rats trained to self-administer intravenous cocaine on a fixed-ratio (FR) 5 schedule of reinforcement. Bromocriptine, a dopamine agonist, produced dose-dependent decreases in cocaine self-administration at doses of 4.0, 8.0, 16.0, and 32.0 mg/kg. In a separate group of rats trained on a DRL 20-second schedule of food reinforcement used to produce the same overall rate of responding for food as for cocaine on the FR 5 schedule, bromocriptine did not produce a significant effect on overall response rate, number of reinforced responses, or percent of responses that were reinforced. Given that bromocriptine produced a specific effect on cocaine-maintained responding, the present results suggest that bromocriptine is interacting with the neurochemical substrate mediating the reinforcing effects of cocaine. The potential effectiveness of bromocriptine as a pharmacotherapy for cocaine dependence is discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317262

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  11 in total

1.  Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially modified by naloxone, bromocriptine, and methysergide.

Authors:  F Weiss; M Mitchiner; F E Bloom; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Involvement of cAMP-dependent protein kinase in the nucleus accumbens in cocaine self-administration and relapse of cocaine-seeking behavior.

Authors:  D W Self; L M Genova; B T Hope; W J Barnhart; J J Spencer; E J Nestler
Journal:  J Neurosci       Date:  1998-03-01       Impact factor: 6.167

3.  Effects of dopamine agonists and antagonists on cocaine-induced operant responding for a cocaine-associated stimulus.

Authors:  R Weissenborn; V Deroche; G F Koob; F Weiss
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

4.  Social defeat stress in rats: escalation of cocaine and "speedball" binge self-administration, but not heroin.

Authors:  Fabio C Cruz; Isabel M Quadros; Koen Hogenelst; Cleopatra S Planeta; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2011-01-04       Impact factor: 4.530

5.  Effects of intra-nucleus accumbens shell administration of dopamine agonists and antagonists on cocaine-taking and cocaine-seeking behaviors in the rat.

Authors:  Ryan K Bachtell; Kimberly Whisler; David Karanian; David W Self
Journal:  Psychopharmacology (Berl)       Date:  2005-10-22       Impact factor: 4.530

6.  Obesity-resistant S5B rats showed greater cocaine conditioned place preference than the obesity-prone OM rats.

Authors:  Panayotis K Thanos; Ronald Kim; Jacob Cho; Michael Michaelides; Brenda J Anderson; Stefany D Primeaux; George A Bray; Gene-Jack Wang; John K Robinson; Nora D Volkow
Journal:  Physiol Behav       Date:  2010-08-27

7.  Mu opioid receptor mRNA in nucleus accumbens is elevated following dopamine receptor activation.

Authors:  A V Azaryan; B J Clock; B M Cox
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

8.  Variability of drug self-administration in rats.

Authors:  Leigh V Panlilio; Jonathan L Katz; Roy W Pickens; Charles W Schindler
Journal:  Psychopharmacology (Berl)       Date:  2003-03-18       Impact factor: 4.530

9.  Treating cocaine addiction with viruses.

Authors:  M Rocio A Carrera; Gunnar F Kaufmann; Jenny M Mee; Michael M Meijler; George F Koob; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-28       Impact factor: 11.205

10.  Transdermal selegiline and intravenous cocaine: safety and interactions.

Authors:  Elisabeth J Houtsmuller; Lisa D Notes; Thomas Newton; Nicolette van Sluis; Nora Chiang; Ahmed Elkashef; George E Bigelow
Journal:  Psychopharmacology (Berl)       Date:  2003-11-06       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.